Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5830-5835

  Guillard, T ^a,b,c   Cambau, E ^b,d   Chau, F ^b   Massias, L ^e   De Champs, C ^a,c   Fantin, B ^b,e  

^a UNIVERSITÉ DE REIMS CHAMPAGNE ARDENNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SERVICE DE DERMATOLOGIE   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; NORFLOXACIN; OFLOXACIN; STREPTOMYCIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ESCHERICHIA COLI; HYDROLYSIS; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PYELONEPHRITIS; SINGLE DRUG DOSE; ANIMAL; ANTIBIOTIC RESISTANCE; BACTERIUM TRANSFORMATION; CBA MOUSE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; FEMALE; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; TREATMENT FAILURE;

ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DNA GYRASE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HYDROLYSIS; MICE; MICE, INBRED CBA; MICROBIAL SENSITIVITY TESTS; MUTATION; PLASMIDS; PYELONEPHRITIS; TRANSFORMATION, BACTERIAL; TREATMENT FAILURE;

EID: 84887481649     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01489-13     Document Type: Article

References (36)

1. Hooper D. 2000. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31(Suppl 2):S24-S28. doi:10.1086/314056.
2. Goossens H. 2009. Antibiotic consumption and link to resistance. Clin. Microbiol. Infect. 15(Suppl 3):12-15.
3. Garau J, Xercavins M, Rodríguez-Carballeira M, Gómez-Vera JR, Coll I, Vidal D, Llovet T, Ruíz-Bremón A. 1999. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob. Agents Chemother. 43:2736-2741.
4. Drlica K, Malik M, Kerns RJ, Zhao X. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392.
5. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. 2009. Plasmidmediated quinolone resistance: a multifaceted threat. Clin. Microbiol. Rev. 22:664-689.
6. Martínez-Martínez L, Pascual A, Jacoby GA. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797-799.
7. Périchon B, Courvalin P, Galimand M. 2007. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob. Agents Chemother. 51:2464-2469.
8. Sørensen AH, Hansen LH, Johannesen E, Sørensen SJ. 2003. Conjugative plasmid conferring resistance to olaquindox. Antimicrob. Agents Chemother. 47:798-799.
9. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Park CH, Bush K, Hooper DC. 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat. Med. 12:83-88.
10. Ma J, Zeng Z, Chen Z, Xu X, Wang X, Deng Y, Lü D, Huang L, Zhang Y, Liu J, Wang M. 2009. High prevalence of plasmid-mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qepA among ceftiofurresistant Enterobacteriaceae isolates from companion and food-producing animals. Antimicrob. Agents Chemother. 53:519-524.
11. European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Dieases (ESCMID). 2000. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin. Microbiol. Infect. 6:509-515.
12. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement M100-S21. CLSI, Wayne, PA.
13. Labat F, Pradillon O, Garry L, Peuchmaur M, Fantin B, Denamur E. 2005. Mutator phenotype confers advantage in Escherichia coli chronic urinary tract infection pathogenesis. FEMS Immunol. Med. Microbiol. 44:317-321.
14. Allou N, Cambau E, Massias L, Chau F, Fantin B. 2009. Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection. Antimicrob. Agents Chemother. 53:4292-4297.
15. Rodríguez-Martínez JM, Pichardo C, García I, Pachón-Ibañez ME, Docobo-Pérez F, Pascual A, Pachón J, Martínez-Martínez L. 2008. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1. Clin. Microbiol. Infect. 14:691-697.
16. Jakobsen L, Cattoir V, Jensen KS, Hammerum AM, Nordmann P, Frimodt-Moller N. 2012. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model. J. Antimicrob. Chemother. 67:2438-2444.
17. Guillard T, Duval V, Moret H, Brasme L, Vernet-Garnier V, de Champs C. 2010. Rapid detection of aac(6')-Ib-cr quinolone resistance gene by pyrosequencing. J. Clin. Microbiol. 48:286-289.
18. Guillard T, Moret H, Brasme L, Carlier A, Vernet-Garnier V, Cambau E, de Champs C. 2011. Rapid detection of qnr and qepA plasmidmediated quinolone resistance genes using real-time PCR. Diagn. Microbiol. Infect. Dis. 70:253-259.
19. Fantin B, Duval X, Massias L, Alavoine L, Chau F, Retout S, Andremont A, Mentré F. 2009. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J. Infect. Dis. 200:390-398.
20. Schentag JJ. 2000. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin. Infect. Dis. 31(Suppl 2):S40-S44. doi:10.1086/314059.
21. Rubinstein E, St Julien L, Ramon J, Dautrey S, Farinotti R, Huneau JF, Carbon C. 1994. The intestinal elimination of ciprofloxacin in the rat. J. Infect. Dis. 169:218-221.
22. Johnson JR, Clermont O, Menard M, Kuskowski MA, Picard B, Denamur E. 2006. Experimental mouse lethality of Escherichia coli isolates, in relation to accessory traits, phylogenetic group, and ecological source. J. Infect. Dis. 194:1141-1150.
23. Stamm WE, Norrby SR. 2001. Urinary tract infections: disease panorama and challenges. J. Infect. Dis. 183(Suppl 1):S1-S4. doi:10.1086/318850.
24. Ronald AR, Nicolle LE, Stamm E, Krieger J, Warren J, Schaeffer A, Naber KG, Hooton TM, Johnson J, Chambers S, Andriole V. 2001. Urinary tract infection in adults: research priorities and strategies. Int. J. Antimicrob. Agents 17:343-348.
25. Yang H, Chen H, Yang Q, Chen M, Wang H. 2008. High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. Antimicrob. Agents Chemother. 52:4268-4273.
26. Jones GL, Warren RE, Skidmore SJ, Davies VA, Gibreel T, Upton M. 2008. Prevalence and distribution of plasmid-mediated quinolone resistance genes in clinical isolates of Escherichia coli lacking extendedspectrum beta-lactamases. J. Antimicrob. Chemother. 62:1245-1251.
27. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. 2006. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacinmodifying enzyme. Antimicrob. Agents Chemother. 50:3953-3955.
28. Endimiani A, Luzzaro F, Perilli M, Lombardi G, Colì A, Tamborini A, Amicosante G, Toniolo A. 2004. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin. Infect. Dis. 38:243-251.
29. Fuursted K, Schumacher H. 2002. Significance of low-level resistance to ciprofloxacin in Klebsiella pneumoniae and the effect of increased dosage of ciprofloxacin in vivo using the rat granuloma pouch model. J. Antimicrob. Chemother. 50:421-424.
30. McCarron B, Love WC. 1997. Acalculous nontyphoidal salmonellal cholecystitis requiring surgical intervention despite ciprofloxacin therapy: report of three cases. Clin. Infect. Dis. 24:707-709.
31. Vasallo FJ, Martín-Rabadán P, Alcalá L, García-Lechuz JM, Rodríguez-Créixems M, Bouza E. 1998. Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clin. Infect. Dis. 26:535-536.
32. Caulin E, Coutrot A, Carbon C, Collatz E. 1996. Resistance to amikacin and isepamicin in rabbits with experimental endocarditis of an aac(6')-Ib-bearing strain of Klebsiella pneumoniae susceptible in vitro. Antimicrob. Agents Chemother. 40:2848-2853.
33. Bergan T. 1990. Extravascular penetration of ciprofloxacin: a review. Diagn. Microbiol. Infect. Dis. 13:103-114.
34. Wachino JI, Yamane K, Arakawa Y. 2011. Practical disk-based method for detection of Escherichia coli clinical isolates producing the fluoroquinolone-modifying enzyme AAC(6')-Ib-cr. J. Clin. Microbiol. 49:2378-2379.
35. Jung CM, Heinze TM, Strakosha R, Elkins CA, Sutherland JB. 2009. Acetylation of fluoroquinolone antimicrobial agents by an Escherichia coli strain isolated from a municipal wastewater treatment plant. J. Appl. Microbiol. 106:564-571.
36. Karah N, Poirel L, Bengtsson S, Sundqvist M, Kahlmeter G, Nordmann P, Sundsfjord A, Samuelsen Ø, Norwegian Study Group on PMQR. 2010. Plasmid-mediated quinolone resistance determinants qnr and aac(6')-Ib-cr in Escherichia coli and Klebsiella spp. from Norway and Sweden. Diagn. Microbiol. Infect. Dis. 66:425-431.